THE APEX TIMES
Johnson & Johnson Earns 5-Star Spot in Newsweek’s World’s Greenest Companies 2026
The healthcare giant was among a group of top-scoring firms cited by Newsweek and Plant-A Insights Group as part of a new environmental sustainability ranking released June 4.
Johnson & Johnson was named among the 5-star winners in Newsweek’s World’s Greenest Companies 2026, a ranking that identifies the top 850 publicly listed companies across 28 countries based on environmental sustainability performance, according to a June 4 announcement. The recognition places the company alongside firms including Goldman Sachs, MetLife, Ralph Lauren, Hitachi, T-Mobile and Zillow, the release said.
Newsweek and Plant-A Insights Group said the 2026 ranking draws on self-disclosed sustainability data and independent research. The study screened more than 8,000 companies before selecting the 850 highest-scoring names for inclusion. The evaluation used information “available up to April 2026,” and it considered only companies whose latest sustainability data were published on or after January 31, 2025, the release stated.
The ranking’s scoring approach relies on analysis across more than 25 parameters organized into four categories: greenhouse gas (GHG) emissions, water usage, waste generation, and sustainability data disclosure and commitments. Newsweek said the assessment also incorporated EU Benchmark exclusion criteria and applied exclusions for certain activity types and controversies, including involvement in controversial weapons, nuclear energy, tobacco, major fossil fuel activities, or environmental misconduct. The release also said companies with fewer than 500 employees were excluded and that Newsweek and Plant-A verified exclusions through media monitoring and review.
A separate Plant-A project page describing the same initiative says the companies are evaluated and scored on more than 25 parameters spanning those four categories. It also says the group used an industry media monitoring platform to screen press coverage for potential issues tied to greenwashing, corporate fraud, regulatory violations, and environmental disasters. The page further states that all winners’ scores and details were verified by Plant-A’s research team and Newsweek’s editorial and rankings team, and that Plant-A maintains a “no-pay-to-play” policy, with no applications required.
For Johnson & Johnson specifically, the company markets its sustainability strategy under its “Health for Humanity” environmental sustainability effort. In its climate action materials, J&J says it reduced the carbon footprint of its operations by 23% between 2021 and 2023. It also reports that 87% of its electricity needs came from renewable sources over that period, and that it reached 100% renewable electricity in the U.S., Canada and Europe. The company also said it avoided approximately 265,000 metric tons of carbon emissions annually through efficiency projects completed between 2005 and 2023.
J&J’s disclosures also describe a continued push toward renewable energy and decarbonization, including an objective to increase renewable electricity usage with a “goal to reach 100% by 2025.” The company also cites efforts aimed at fleet electrification and supplier engagement on decarbonization strategies, and it references a “CO2 Capital Relief Program” described as continued investment of up to $40 million per year in low-carbon technologies and operational energy efficiency. Those items speak to the types of emissions, operational efficiency, and disclosure topics that environmental rankings typically weight heavily.
Even with the new recognition, the public release does not disclose Johnson & Johnson’s specific score, category breakdown, or whether its 5-star designation reflects particular year-over-year improvements versus overall standing. The Newsweek methodology summary also emphasizes that scores are derived from publicly available sustainability reporting, which means differences in how companies measure and report data can affect comparability across industries. What is clear is that the ranking is centered on disclosed sustainability metrics, screened by eligibility rules and exclusion criteria, and capped at the top-scoring 850 firms worldwide.
Why It Matters
- For large consumer and healthcare brands, sustainability rankings can influence procurement discussions and reputation assessments, even when they are not tied to regulatory outcomes.
- The Newsweek methodology underscores that public sustainability reporting quality and completeness may be a key driver of inclusion and scoring.
- Recognition alongside finance and consumer companies highlights that cross-industry environmental metrics are being treated as a mainstream corporate benchmark.
- Because the release does not provide Johnson & Johnson’s category scorecard, investors and analysts may still need to rely on the company’s own sustainability reporting for verification of progress.
Sources
- announcement (Yahoo Finance RSS copy of GlobeNewswire release)
- GlobeNewswire: Newsweek and Plant-A release detailing World’s Greenest Companies 2026 methodology and winners
- Plant-A Insights Group project page for World’s Greenest Companies 2026 methodology overview
- Johnson & Johnson: Health for Humanity global environmental sustainability goals page
- Image
Key Facts
- Newsweek, in partnership with Plant-A Insights Group, announced its World’s Greenest Companies 2026 rankings, recognizing the top 850 publicly listed firms across 28 countries.
- Johnson & Johnson was cited among the publication’s 5-star winners in the 2026 list.
- The ranking is based on self-disclosed sustainability data and independent research, using information available up to April 2026.
- Companies were required to have their latest sustainability data published on or after January 31, 2025, to be considered eligible.
- Scoring categories include greenhouse gas emissions, water usage, waste generation, and sustainability data disclosure and commitments.
- Newsweek and Plant-A applied EU Benchmark exclusion criteria and excluded companies with fewer than 500 employees.
Healthcare Related
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.
Pfizer highlights Padcev while pushing forward PF-08634404 as part of its longer-term oncology plan
A new market report frames Pfizer’s near-term oncology momentum around Padcev, while pointing to PF-08634404 and potential label expansion efforts as catalysts the company expects to matter later.